What does an RNA drug platform cost when the supply suddenly shrinks? Merck KGaA just answered that question with a $1.3 billion all-cash bid for Silence Therapeutics, and the timing makes the price at least as interesting as the science.
The transaction values Silence at approximately $1.3 billion, with Merck KGaA offering $20.00 per American depositary share in cash, representing a 130% premium to Silence’s closing ADS price on October 16, 2026. The offer also represents an 82% premium to the 30-day volume-weighted average price of $10.99. Silence shareholders who held through Friday are being paid double. The stock’s reaction said the rest: Silence ADS shares leapt more than 125% in premarket trading on Monday, October 19, 2026.
Why the Platform Matters
Silence is not just a drug developer. Its mRNAi GOLD platform is a GalNAc-conjugated siRNA delivery engine built over two decades, and the headline asset, divesiran, is the proof of concept. The Phase 2 SANRECO trial met its primary endpoint, with 88% of divesiran-treated patients achieving a clinical response in phlebotomy-dependent polycythemia vera, while phlebotomy burden dropped to 0.2 versus 2.1 mean procedures through week 36. That is the kind of data that makes a Phase 3 feel obligatory rather than speculative.
With Takeda projecting its competing polycythemia vera drug reaching $1 billion to $2 billion in peak revenue potential, analysts noted the Silence deal appears inexpensive considering Merck also acquires the biotech’s siRNA platform technology. Merck KGaA is not just buying one drug. It is buying the machine that could generate several more.
The Context That Changes Everything
Three days before this deal was announced, Beijing moved to wall off its own RNA assets. China’s government revealed a draft policy that would block foreign acquisitions of proprietary cell and gene therapy, siRNA, and pathogen gain-of-function platforms. Platforms, in this context, are defined as sets of reusable technologies that can support the development of multiple drugs.
The scale of what is now off-limits matters. Claims about how much of 2026 large-cap upfront licensing dollars came from China-origin assets vary by dataset and methodology, so treat any single percentage with caution. Still, the direction is clear: China-origin biopharma assets have been a growing source of global deal flow. Under the draft policy, a European buyer can generally still license Chinese assets, but acquiring the Chinese company that owns a covered platform would be restricted or prohibited. That constraint concentrates value in Western-domiciled platforms sharply. Silence, headquartered in London, sits outside Beijing’s perimeter.
Who Else Gets Priced In
The Silence deal is a reference point, not an endpoint. Arrowhead Pharmaceuticals achieved its first FDA approval in November 2025 with plozasiran, validating its TRiM platform as a credible alternative to Alnylam’s. Alnylam holds one of the deepest siRNA portfolios, spanning multiple marketed drugs and partnered programs. Both companies own what Beijing has just decided it will not let foreign buyers acquire from Chinese peers.
Merck KGaA itself acknowledged the strategic logic directly. CEO Kai Beckmann described the acquisition as strengthening capabilities for targeted specialty and rare diseases, following the July 1, 2025, acquisition of SpringWorks Therapeutics as part of an ongoing transformation toward high-specialization and unmet medical need.
What Could Go Wrong
The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions including regulatory approvals and Silence shareholder approval. Arb desks have priced the residual close risk at roughly 2%, implying a roughly 4% to 5% annualized return if the deal completes on schedule. That is the floor risk. The bigger question is whether divesiran’s Phase 3 delivers the same 88% response rate at scale, and whether Merck KGaA can move quickly enough in polycythemia vera before a competitor like Takeda builds durable market share.
Bottom Line
Merck KGaA paid a 130% premium because the combination of proven GalNAc-siRNA chemistry, Phase 2 data that would clear most acquirer hurdles, and a supply of acquirable Western platforms that just got materially smaller left them little choice. The question for investors watching Alnylam and Arrowhead is whether this deal resets the floor for what a credentialed RNA platform commands, at a moment when the largest source of competing assets has been placed behind a regulatory wall.
